Private Placements

 

 

 

 

Hedge Funds

 

 

 

 

Jupiter Orphan Therapeutics, Inc.

 

 

 

Business: JOT is a clinical stage, drug platform company focused on developing treatments for Alzheimers Disease as well as targeted rare diseases.

 

JOT has developed a unique platform product, JOTROL(TM), which is a patented reformulation of the well-known wonder medication resveratrol. JOTROL(TM) is the first and only resveratrol product in the world that can deliver a therapeutically effective dose without causing GI side effects. Resveratrol, delivered by JOTROL(TM) into blood plasma, crosses the blood brain barrier, helping alleviate a number of central nervous system symptoms associated with many diseases. Resveratrol in high plasma levels has a multifunctional mechanism of action, including anti-inflammatory and boost of Mitochondrial biogenesis, which is expected to be beneficial for treatment of Alzheimers Disease as well as several rare diseases. Key events:

 

 

o

US and European patents issued, China and Japan pending.

 

 

o

IND approved by FDA with Safe to Proceed statement.

 

 

o

NIA/NIH grant of $1.76 million received for Phase I study in Alzheimers Disease.

 

 

o

Phase I results expected in Q1, 2021.

 

Chairman, CEO, & Primary Founder: Christer Rosen. His past business ventures include founding Effrx Pharmaceuticals as well as 10 companies in various industries. He has more than 20 years of pharma experience and is one of few individuals who invented a pharmaceutical product (Binosto); developed it; received marketing approval by the FDA, EU, MENA, and Asian markets; and sold it through distribution partners around the world. Specialist in bringing together extraordinary teams in a virtual setting.

 

Size & Type of Offering: Series A of $2.5 million in equity.

 

Website

 

News

 

Offices: Jupiter, Florida

 

Contact: info@jupiterorphan.com

 

 

 

Index of Private Placements & Hedge Funds

 

PBHFA Home

 

Here is a link to information on our comprehensive investor awareness program.

For more detailed information, please contact one of the following individuals:

 

William J. Ritger at 561.891.1903 or writger@gmail.com

David Goodboy at 561.349.7300 or dave@pbhfa.org

 

 

The Deal Flow section of this website is operated jointly by Palm Beach Hedge Fund Association, Inc., a Florida corporation, and TickerBuzz, LLC, a Florida limited liability company. Neither PBHFA nor TickerBuzz are registered broker-dealers, and they do not give investment advice, endorsement, analysis, or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this site is the responsibility of the applicable issuer of such securities. Neither PBHFA nor TickerBuzz have taken any steps to verify the adequacy, accuracy, or completeness of any information, and neither PBHFA nor TickerBuzz nor any of their officers, directors, agents, and employees make any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the PBHFA Terms of Use and Privacy Policy. Neither PBHFA nor TickerBuzz make investment recommendations, and no communication, through this website or in any other medium, should be construed as a recommendation for any security offered on or off this investment platform. Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments through equity crowdfunding tend to be in earlier stages of development, and their business model, products, and services may not yet be fully developed, operational, or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns. In the most sensible investment strategy for start-up investing, start-ups should only be part of your overall investment portfolio. Further, the start-up portion of your portfolio may include a balanced portfolio of different start-ups. Investments in start-ups are highly illiquid, and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

 

This Profile is intended for discussion purposes only; the only definitive source of information regarding this offering is the Company offering documents. This Profile is not a solicitation to buy or sell any security, and must not be relied upon for financial, legal, tax, or any other professional advice. Investor prospects should also carefully research and consider the risks inherent in this investment. The information in this Profile is applicable only as of the date of this Profile and is subject to change without prior notice. Past performance is not indicative of future results. The editor of this Profile is a Managing Member of TickerBuzz. This Company has not paid any fee for this Company Profile. Neither PBHFA nor TickerBuzz take any compensation relating to the success of any securities offering. October 29, 2020.

 

 

 

Web Hits